Eligibility Matched Benchmarking of Second-Line Anti-CD19 CAR-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.
Comparing CAR-T outcomes to a major trial's bispecific antibody results helps doctors weigh second-line lymphoma therapy options in real practice.
This comparative effectiveness letter benchmarks second-line anti-CD19 CAR T-cell therapy outcomes from a real-world Israeli multicenter experience against the glofitamab + GemOx arm of the STARGLO trial using eligibility matching. The analysis addresses an important clinical question about optimal second-line therapy sequencing in R/R LBCL where both CAR-T and bispecific antibody-based regimens are now available options.
What the study was
- Study design
- Comparative effectiveness study (eligibility-matched benchmarking)
- Population
- R/R LBCL patients receiving second-line anti-CD19 CAR T-cell therapy benchmarked against STARGLO trial glofitamab + GemOx arm
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
Comparative effectiveness benchmarking of CAR-T vs bispecific in second-line LBCL; clinically relevant treatment sequencing data from Israeli multicenter experience.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.